LexDanaLexDanabeta
Inventor

Pele Chong

Inventor
Richmond Hill, CA

Overview

85→
Patents
1995–2019
Patent span
Chemistry
Primary field (CPC C)

Patents· 85 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes22%
C07KPeptides19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%
C12NMicroorganisms or enzymes17%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests7%
Y02ATechnologies for adaptation to climate change5%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds2%
Y10TTechnical subjects covered by former us classification2%
C07HSugars1%
PatentTitleYear
10,406,221Lipidated 201910,287,328Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same201910,172,945Sorbitan polyester conjugates for stabilizing water-in-oil emulsions and delivering controlled release of bioactive agents201910,004,796Adenoviral vector-based vaccine against enterovirus infection20189,493,518'Compositions and methods for treating clostridium difficile-associated diseases'20169,415,069'Immunosuppressive cells and methods of making and using thereof'20169,095,546'Human respiratory syncytial virus (RSV) vaccine'20159,051,361'Immunogenic compositions and uses thereof'20158,771,990'Method of producing lipidated polypeptides'20148,716,512'Preparation and purification of subunit vaccine for Neisseria meningitidis (NM) group B isolates'20148,658,767'Lipidated polyepitope vaccines'20148,658,176'Lipidated tumor-associated antigens and immunotherapeutic compositions'20148,466,259'Adjuvants'20138,465,756'Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy'20138,460,680'Polyvalent chimeric rubella virus-based vaccines'20138,444,993'Multi-phase emulsions based on amphiphilic block copolymers'20138,426,163'Production of lipidated proteins in E. coli '20138,287,880'Lipidated vaccine against dengue virus infection'20127,981,431'Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use'20117,931,906'Vero cell-based influenza virus strains and vaccines'20117,833,776'Lipidating sequences and use thereof for producing lipidated proteins in E. coli '20107,491,397'Receptor binding polypeptides'20097,342,090'Fab-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5'20087,118,749'Transferrin receptor genes'20067,105,164'HIV-specific cytotoxic T-cell responses'20067,018,637'Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines'20066,764,682'Adjuvant compositions containing more than one adjuvant'20046,656,472'Multi oligosaccharide glycoconjugate bacterial meningitis vaccines'20036,623,764'Biodegradable targetable microparticle delivery system'20036,482,928'Fab-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5'20026,471,996'Biodegradable targetable microparticle delivery system'20026,448,386'High molecular weight major outer membrane protein of moraxella'20026,444,211'Purification of a pertussis outer membrane protein'20026,440,425'High molecular weight major outer membrane protein of moraxella'20026,361,779'Transferrin receptor genes'20026,358,727'Haemophilus transferrin receptor genes'20026,312,732'Biodegradable targetable microparticle delivery system'20016,290,971'Adjuvant compositions comprising a mineral salt and another immunostimulating compound'20016,287,604'Biodegradable targetable microparticle delivery system'20016,264,954'Haemophilus outer membrane protein'20016,262,016'Transferrin receptor genes'20016,228,423'Biodegradable targetable microparticle delivery system'20016,224,881'DNA molecule fragments encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof'20016,180,758'Synthetic peptides for rubella vaccine'20016,153,580'Analog of haemophilus Hin47 with reduced protease activity'20006,147,057'Analog of Haemophilus Hin47 with reduced protease activity'20006,114,125'Analog of Haemophilus Hin47 with reduced protease activity'20006,083,743'Haemophilus outer membrane protein'20006,080,589'Neisseria meningitidis capsular polysacchride conjugates'20006,042,820'Biodegradable copolymer containing .alpha.-hydroxy acid and .alpha.-amino acid units'20006,037,448'Synthetic peptides for a rubella vaccine'20006,025,342'Analog of Haemophilus Hin47 with reduced protease activity'20006,020,183'Analog of haemophilus Hin47 with reduced protease activity'20006,018,019'Synthetic Haemophilus influenzae conjugate vaccine'20006,015,688'Transferrin receptor genes'20006,013,514'Haemophilus outer membrane protein'20006,008,326'Transferrin receptor antibodies'19995,985,288'Outer membrane protein P1 and peptides of Haemophilus influenzae type B'19995,981,503'Analog of Haemophilus Hin47 with reduced protease activity'19995,972,349'Synthesis of polyribosylribitol phosphate oligosaccharides'19995,962,430'Analog of Haemophilus Hin47 with reduced protease activity'19995,951,986'Tandem synthetic HIV-1 peptides'19995,939,297'Analog of haemophilus HIN47 with reduced protease activity'19995,935,573'Method of use of an analog of Haemophilus influenzae Hin47 with reduced protease activity'19995,922,841'Recombinantly produced transferrin receptor of haemophilus'19995,922,323'Transferrin receptor genes and immunogenic compositions derived therefrom'19995,922,562'Nucleic acids encoding transferrin receptors'19995,916,562'Membrane proteins and peptides of haemophilus influenzae type B'19995,876,731'Tandem synthetic HIV-1 Peptides'19995,869,302'Analog of haemophilus hin47 with reduced protease activity'19995,837,250'Adjuvant compositions'19985,817,318'Synthetic peptides for an HIV-1 vaccine'19985,817,754'Tandem synthetic HIV-1 peptide'19985,800,822'Tandem synthetic HIV-1 peptides'19985,795,955'Tandem synthetic HIV-1 peptides'19985,780,606'Neisseria meningitidis capsular polysaccharide conjugates'19985,759,769'Tandem synthetic HIV-1 peptides'19985,708,149'Method for producing purified recombinant Haemophilus influenzae transferrin binding proteins'19985,679,352'Synthetic Haemophilus influenzae conjugate vaccine'19975,667,787'Purification of a pertussis outer membrane protein'19975,665,353'Composition containing an analog of haemophilus Hin47 with reduced protease activity'19975,656,436'Analog of Haemophilus Hin47 with reduced protease activity'19975,639,854'Tandem synthetic HIV-1 peptides'19975,506,139'Analog of haemophilus Hin47 with reduced protease activity'19965,444,159'Purification of a pertussis outer membrane protein'1995

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1995–2006Patents assigned to CONNAUGHT LAB (44)· patent assignee history
1995–2002Based in Thornhill, CA· patent location history
1996–2009Based in Richmond Hill, CA· patent location history
2001–2004Patents assigned to AVENTIS PASTEUR (11)· patent assignee history
2009–2016Patents assigned to NAT HEALTH RESEARCH INSTITUTES (18)· patent assignee history
2010–2019Based in Miao-Li County, TW· patent location history
2011–2019Based in Zhunan Town, TW· patent location history
2012–2015Patents assigned to CHONG PELE CHOI-SING (11)· patent assignee history
2012–2014Patents assigned to LENG CHIH-HSIANG (9)· patent assignee history
2019Based in Toronto, CA· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CONNAUGHT LAB441995–2006
NAT HEALTH RESEARCH INSTITUTES182009–2016
AVENTIS PASTEUR112001–2004
CHONG PELE CHOI-SINGself112012–2015
LENG CHIH-HSIANG92012–2014
Locations
LocationPatentsSpan
Richmond Hill, CA591996–2009
Miao-Li County, TW132010–2019
Zhunan Town, TW72011–2019
Thornhill, CA51995–2002
Toronto, CA12019